Treatment for Colorectal Carcinoma
Study Summary
This trial is testing a new cancer drug, DKN-01, to see if it is more effective than the current standard of care for treating advanced colorectal cancer.
- Colorectal Carcinoma
- Metastatic Colorectal Cancer (CRC)
Treatment Effectiveness
Study Objectives
2 Primary · 4 Secondary · Reporting Duration: approximately 6 months
Trial Safety
Trial Design
2 Treatment Groups
Control
1 of 2
Treatment
1 of 2
Active Control
Experimental Treatment
150 Total Participants · 2 Treatment Groups
Primary Treatment: Treatment · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 14th, 2021
Last Reviewed: November 8th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.